The role of mannose binding lectin on fever episodes in pediatric oncology patients Ferenc Fekete Email author Balázs Fadgyas Éva Papp Ágnes Szilágyi Zoltán Prohászka Brigitta Müller Gábor Kovács Original Article First Online: 03 October 2015 Received: 09 February 2014 Accepted: 01 October 2015 DOI :
10.1007/s12253-015-9992-x
Cite this article as: Fekete, F., Fadgyas, B., Papp, É. et al. Pathol. Oncol. Res. (2016) 22: 139. doi:10.1007/s12253-015-9992-x Abstract Despite significant changes in pediatric oncological therapy, mortality is still high, mainly due to infections. Complement system as an ancient immune defense against microorganisms plays a significant role in surmounting infections, therefore, deficiency of its components may have particular importance in malignancies. The present paper assesses the effect of promoter (X/Y) and exon 1 (A/0) polymorphisms of the MBL2 gene altering mannose binding lectin (MBL) serum level in pediatric oncological patients with febrile neutropenia. Furthermore, frequency distribution of MBL2 alleles in children with malignancies and age-matched controls was analysed. Fifty-four oncohematological patients and 53 children who had undergone pediatric surgery were enrolled into this retrospective study. No significant differences were found in the frequency of MBL2 alleles between the hemato-oncologic and control group. The average duration of fever episodes was significantly shorter (p = 0.035) in patients carrying genotypes (AY/AY and AY/AX) that encode normal MBL level, compared to individuals with genotypes associated with lower functional MBL level (AX/AX, AY/0, AX/0, or 0/0) (days, median (IQ range) 3.7(0–5.4) vs. 5.0(3.8–6.6), respectively). In conclusion, our data suggest that MBL2 genotypes may influence the course of febrile neutropenia in pediatric patients with malignancies, and may contribute to clarification of the importance of MBL in infections.
Keywords MBL Polymorphism Febrile neutropenia Oncohematology
References 1.
Walport MJ (2001) Complement Second of two parts. N Engl J Med 344:1140–1144
CrossRef PubMed Google Scholar 2.
Walport MJ (2001) Complement First of two parts. N Engl J Med 344:1058–1066
CrossRef PubMed Google Scholar 3.
Neth O, Jack DL, Dodds AW, et al. (2000) Mannose-binding lectin binds to a range of clinically relevant microorganisms and promotes complement deposition. Infect Immun 68:688–693
PubMedCentral CrossRef PubMed Google Scholar 4.
Garred P (2008) Mannose-binding lectin genetics: from a to Z. Biochem Soc Trans 36:1461–1466
CrossRef PubMed Google Scholar 5.
Garred P, Larsen F, Madsen HO, et al. (2003) Mannose-binding lectin deficiency–revisited. Mol Immunol 40:73–84
CrossRef PubMed Google Scholar 6.
Bouwman, LH, Roep, BO & Roos, (2006) A Mannose-binding lectin: clinical implications for infection, transplantation, and autoimmunity. Hum Immunol. 67:247–256.
7.
Ruskamp JM, Hoekstra MO, Rovers MM, et al. (2006) (2006) mannose-binding lectin and upper respiratory tract infections in children and adolescents: a review. Arch Otolaryngol Head Neck Surg 132:482–486
CrossRef PubMed Google Scholar 8.
Koutsounaki E, Goulielmos GN, Koulentaki M, et al. (2008) Mannose-binding lectin MBL2 gene polymorphisms and outcome of hepatitis C virus-infected patients. J Clin Immunol 28:495–500
CrossRef PubMed Google Scholar 9.
Garred P, S J,J, Quist L, et al (2003) Association of mannose-binding lectin polymorphisms with sepsis and fatal outcome, in patients with systemic inflammatory response syndrome. J Infect Dis 188:1394–1403
CrossRef PubMed Google Scholar 10.
Schmiegelow K, Garred P, Lausen B, et al. (2002) Increased frequency of mannose-binding lectin insufficiency among children with acute lymphoblastic leukemia. Blood 100:3757–3760
CrossRef PubMed Google Scholar 11.
Neth O, Hann I, Turner MW, et al. (2001) Deficiency of mannose-binding lectin and burden of infection in children with malignancy: a prospective study. Lancet 358:614–618
CrossRef PubMed Google Scholar 12.
Ghazi M, Isadyar M, Gachkar L, et al. (2012) Serum levels of mannose-binding lectin and the risk of infection in pediatric oncology patients with chemotherapy. J Pediatr Hematol Oncol 34:128–130
CrossRef PubMed Google Scholar 13.
Horiuchi T, Gondo H, Miyagawa H, et al. (2005) Association of MBL gene polymorphisms with major bacterial infection in patients treated with high-dose chemotherapy and autologous PBSCT. Genes Immun 6:162–166
CrossRef PubMed Google Scholar 14.
Peterslund NA, Koch C, Jensenius JC, et al. (2001) Association between deficiency of mannose-binding lectin and severe infections after chemotherapy. Lancet 358:637–638
CrossRef PubMed Google Scholar 15.
Vekemans M, Robinson J, Georgala A, et al. (2007) Low mannose-binding lectin concentration is associated with severe infection in patients with hematological cancer who are undergoing chemotherapy. Clin Infect Dis 44:1593–1601
CrossRef PubMed Google Scholar 16.
Frakking FN, Brouwer N, Dolman KM, et al. (2011) Mannose-binding lectin (MBL) as prognostic factor in paediatric oncology patients. Clin Exp Immunol 165:51–59
PubMedCentral CrossRef PubMed Google Scholar 17.
Bergmann OJ, Christiansen M, Laursen I, et al. (2003) Low levels of mannose-binding lectin do not affect occurrence of severe infections or duration of fever in acute myeloid leukaemia during remission induction therapy. Eur J Haematol 70:91–97
CrossRef PubMed Google Scholar 18.
Lausen B, Schmiegelow K, Andreassen B, et al. (2006) Infections during induction therapy of childhood acute lymphoblastic leukemia–no association to mannose-binding lectin deficiency. Eur J Haematol 76:481–487
CrossRef PubMed Google Scholar 19.
Martinez-Lopez J, Rivero A, Rapado I, et al. (2009) Influence of MBL-2 mutations in the infection risk of patients with follicular lymphoma treated with rituximab, fludarabine, and cyclophosphamide. Leuk Lymphoma 50:1283–1289
CrossRef PubMed Google Scholar 20.
Rubnitz JE, Howard SC, Willis J, et al. (2008) Baseline mannose binding lectin levels may not predict infection among children with leukemia. Pediatr Blood Cancer 50:866–868
CrossRef PubMed Google Scholar 21.
Zehnder, A, Fisch, U, Hirt, A, et al. (2009) prognosis in pediatric hematologic malignancies is associated with serum concentration of mannose-binding lectin-associated serine protease-2 (MASP-2). Pediatr Blood Cancer. 2009;53:53–57.
22.
Frakking FN, Israels J, Kremer LC, et al. (2011) Mannose-binding lectin (MBL) and the risk for febrile neutropenia and infection in pediatric oncology patients with chemotherapy. Pediatr Blood Cancer 57:89–96
CrossRef PubMed Google Scholar 23.
Bang P, Laursen I, Thornberg K, et al. (2008) (2008) the pharmacokinetic profile of plasma-derived mannan-binding lectin in healthy adult volunteers and patients with Staphylococcus aureus septicaemia. Scand J Infect Dis 40:44–48
CrossRef PubMed Google Scholar 24.
Frakking FN, Brouwer N, van de Wetering MD, et al. (2009) Safety and pharmacokinetics of plasma-derived mannose-binding lectin (MBL) substitution in children with chemotherapy-induced neutropaenia. Eur J Cancer 45:505–512
CrossRef PubMed Google Scholar 25.
Valdimarsson H (2003) Infusion of plasma-derived mannan-binding lectin (MBL) into MBL-deficient humans. Biochem Soc Trans 31:768–769
CrossRef PubMed Google Scholar © Arányi Lajos Foundation 2015
Authors and Affiliations Ferenc Fekete Email author Balázs Fadgyas Éva Papp Ágnes Szilágyi Zoltán Prohászka Brigitta Müller Gábor Kovács 1. Department of Hematology Heim Pál Children’s Hospital Budapest Hungary 2. Department of Pediatric Surgery and Traumatology Heim Pál Children’s Hospital Budapest Hungary 3. National Institute of Psychiatry and Addictions Gyula Nyírő Hospital Budapest Hungary 4. 3rd Department of Internal Medicine, Research Laboratory Semmelweis University Budapest Hungary 5. 2nd Department of Pediatrics, Hematology Unit Semmelweis University Budapest Hungary